RESUMO
BACKGROUND: The monoclonal antibody, 5H7, is specific for a monomorphic determinant on the a3 domain of human class I MHC (A, B, C). Immobilized 5H7 delivers programmed cell death (PCD) signals to human lymphoid tumor cells as well as peripheral blood mononuclear cells. METHODS: The potential clinical utility of 5H7 was addressed by design of a single-chain variable antibody (scFv), termed 5H7scFv, which was coupled to glycophosphotidylinostitol (GPI), thereby providing membrane expression of the 5H7 idiotype (5H7scFv-GPI). Membrane expression of 5H7scFv-GPI conferred PCD-inducing properties to cells that do not normally have the capability to process and express whole antibody molecules. The initial construction was undertaken in a bacterial expression system, and appropriate protein folding was determined by binding to class I MHC-expressing cells. RESULTS: 5H7scFv-GPI-transfected Chinese hamster ovary cells demonstrated reconstitution of the 5H7 idiotype and binding to soluble HLA-A2. Cross-linking of class I MHC, via membrane expression of the scFv, provided effective PCD signaling in B and T lymphocyte tumor cells. Peripheral blood mononuclear cells were susceptible to 5H7scFv-GPI-induced PCD, and augmentation of PCD signals was noted with anti-CD3 and anti-CD28 preactivation. Responder cells demonstrated typical histologic features of PCD and Annexin V-fluorescein isothiocyanate binding. CONCLUSIONS: Cell surface anchorage of scFv thus provides effective delivery of immune modulatory signals, which may be manipulated for various therapeutic strategies.
Assuntos
Anticorpos Monoclonais/imunologia , Apoptose/fisiologia , Região Variável de Imunoglobulina/genética , Proteínas de Membrana/biossíntese , Animais , Anexina A5/análise , Anticorpos Anti-Idiotípicos/imunologia , Anticorpos Anti-Idiotípicos/metabolismo , Especificidade de Anticorpos , Sítios de Ligação de Anticorpos , Células CHO , Técnicas de Cocultura , Cricetinae , Citometria de Fluxo , Expressão Gênica , Antígenos de Histocompatibilidade Classe I/biossíntese , Humanos , Tecido Linfoide/citologia , Fosfatidilinositóis/metabolismo , Transfecção , Transgenes , Células Tumorais CultivadasAssuntos
Anticorpos Monoclonais/farmacologia , Linfócitos T CD4-Positivos/imunologia , Integrinas/fisiologia , Ligantes , Transdução de Sinais/imunologia , Linfócitos T/imunologia , Linfócitos T CD4-Positivos/citologia , Humanos , Integrinas/imunologia , Células Jurkat , Linfócitos T/citologia , Molécula 1 de Adesão de Célula Vascular/fisiologiaRESUMO
Interferon-beta (IFN-beta) exposure during tumour necrosis factor-alpha (TNF-alpha)-induced human monocyte-derived dendritic cell (DC) maturation augments the capacity of DC to promote the generation of T helper 1 (Th1) cells, while IFN-beta exposure during naive Th cell stimulation inhibits Th1 cell generation (Nagai et al., J Immunol, 2003 171:5233-43). Investigating these contradictory outcomes of IFN-beta exposure, we find that isolated DC matured with both TNF-alpha and IFN-beta secrete more IL-12 p70 upon CD40L stimulation than DC matured with TNF-alpha alone. mAb blocking studies indicate that the basis for this enhanced IL-12 p70 production is augmentation of two successive CD40-dependent autocrine pathways in the DC: (1) a pathway in which low levels of IL-12 p70, IL-27, IL-18 and, possibly, IL-23 act to mediate autocrine induction of DC IFN-gamma secretion; and (2) an IFN-gamma-initiated autocrine pathway promoting optimal DC IL-12 p70 secretion. In contrast to the IL-12 p70 promoting effects of IFN-beta during DC maturation, IFN-beta pre-treatment before CD40L stimulation was found to inhibit IFN-gamma-mediated enhancement of DC IL-12 p70 secretion. Thus, IFN-beta exposure during TNF-alpha-mediated DC maturation may promote Th1 polarization by increasing DC IL-12 p70 secretion, through enhancement of autocrine-acting IFN-gamma production by the DC. Moreover, IFN-beta exposure during naive Th cell stimulation may inhibit Th1 cell generation by blocking the IFN-gamma-induced signals required for optimal CD40L-induced DC IL-12 p70 secretion. IFN-beta pre-treatment was also observed to inhibit CD40L-induced DC IL-23 secretion. Our findings may account for some of the beneficial effects of IFN-beta therapy in patients with relapsing remitting multiple sclerosis.
Assuntos
Células Dendríticas/imunologia , Interferon beta/farmacologia , Interferon gama/metabolismo , Interleucina-12/metabolismo , Células Th1/imunologia , Ligante de CD40/farmacologia , Polaridade Celular , Células Dendríticas/efeitos dos fármacos , Humanos , Interferon gama/farmacologia , Interleucina-18/metabolismo , Interleucinas/metabolismo , Monócitos/imunologia , Fator de Necrose Tumoral alfa/farmacologiaRESUMO
Beta1 integrins can provide T cell co-stimulation, but little is known concerning their downstream signaling pathways. We found that Pyk2, a focal adhesion kinase-related tyrosine kinase, is regulated by beta1 integrin signaling in human T cells. Stimulation of Jurkat T cells with the alpha4beta1 integrin ligand VCAM-1 results in Pyk2 tyrosine phosphorylation, and combined stimulation with VCAM-1 and anti-CD3 mAb induces rapid and sustained synergistic Pyk2 phosphorylation. Studies with mAb suggest that in synergistic CD3- and alpha4beta1 integrin-mediated Pyk2 tyrosine phosphorylation, a major contribution of CD3-derived signals is independent of their effects on regulating integrin adhesion. Analysis of resting human CD4+ T cells confirmed the ability of CD3-derived signals to synergize with beta1 integrin-dependent signals in the induction of Pyk2 tyrosine phosphorylation. In addition, although CD28-mediated co-stimulatory signals were able to synergize with CD3-mediated signals in inducing ERK and JNK activation and secretion of IL-2 in the primary T cells, they did not contribute to the induction of Pyk2 phosphorylation. Taken together, these results indicate a potential role for Pyk2 in T cell co-stimulation mediated specifically by beta1 integrins.
Assuntos
Antígenos CD28/fisiologia , Linfócitos T CD4-Positivos/imunologia , Moléculas de Adesão Celular/metabolismo , Integrina beta1/fisiologia , Proteínas Quinases JNK Ativadas por Mitógeno , Quinases de Proteína Quinase Ativadas por Mitógeno , Proteínas Tirosina Quinases/metabolismo , Complexo CD3/fisiologia , Adesão Celular , Ativação Enzimática , Quinase 1 de Adesão Focal , Proteína-Tirosina Quinases de Adesão Focal , Humanos , Células Jurkat , Ativação Linfocitária , MAP Quinase Quinase 4 , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Fosforilação , Proteínas Quinases/metabolismo , Tirosina/metabolismo , Molécula 1 de Adesão de Célula Vascular/fisiologiaRESUMO
Dendritic cell (DC) precursors and immature DC reside in epithelium where they encounter pathogens and cytokines, which stimulate their differentiation. We hypothesized that type-I interferons (IFN-alpha and -beta), cytokines that are produced early in the innate immune response against viruses and some bacteria, may influence DC differentiation and function. To examine this possibility, we used an in vitro model of DC differentiation in which initial culture of human CD14(+) monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 generates immature DC, and subsequent culture with tumor necrosis factor (TNF)-alpha drives the final development into mature DC. We found in this model that IFN-alpha/beta, added from the initiation of the culture on, significantly reduced the survival and altered the morphology and differentiation of DC. TNF-alpha-dependent maturation of IFN-beta-treated immature DC led to cells with reduced expression of CD1a, CD40, CD54, and CD80 when compared with mature DC controls. IFN-alpha/beta-treated DC further had a reduced capacity to induce naive Th-cell proliferation through allostimulation or anti-CD3 monoclonal antibody stimulation. In addition, IFN-alpha/beta-treated DC secreted less IL-12 upon stimulation with Staphylococcus aureus Cowan strain or with CD4(+) T cells, and this decrease correlated directly with their inability to support CD4(+) T-cell secretion of IFN-gamma, even though T-cell lymphotoxin production was unaffected. These findings indicate that type-I IFNs can influence the generation of acquired immune responses by modifying T-helper cell differentiation through the regulation of DC differentiation and function.
Assuntos
Linfócitos T CD4-Positivos/imunologia , Células Dendríticas/citologia , Células Dendríticas/imunologia , Interferon Tipo I/farmacologia , Interferon-alfa/farmacologia , Receptores de Lipopolissacarídeos/sangue , Monócitos/citologia , Antígenos CD/sangue , Diferenciação Celular/efeitos dos fármacos , Diferenciação Celular/imunologia , Células Cultivadas , Células Dendríticas/efeitos dos fármacos , Humanos , Imunocompetência , Interleucina-2/biossíntese , Cinética , Ativação Linfocitária , Monócitos/efeitos dos fármacos , Monócitos/imunologia , Proteínas RecombinantesRESUMO
Complete T cell activation requires not only a first signal via TCR/CD3 engagement but also a costimulatory signal through accessory receptors such as CD2, CD28, or integrins. Focal adhesion kinase, pp125(FAK) (FAK), was previously shown to be localized in focal adhesions in fibroblasts and to be involved in integrin-mediated cellular activation. Although signaling through beta1- or beta3-integrins induces tyrosine phosphorylation of FAK, there has been no evidence that activation of T cells through the beta2-integrin, LFA-1, involves FAK. We report here that crosslinking of LFA-1 induces tyrosine phosphorylation of FAK in PHA-activated T cells. Moreover, cocrosslinking with anti-LFA-1 mAb and suboptimal concentration of anti-CD3 mAb markedly increases tyrosine phosphorylation of FAK in an antibody-concentration-dependent and time-kinetics-dependent manner compared with stimulation through CD3 alone, which correlates well with enhanced proliferation of PHA-activated T cells. Furthermore, LFA-1beta costimulation with CD3 induces tyrosine phosphorylation of Syk associated with FAK. These results indicate, for the first time, that signals mediated by LFA-1 can regulate FAK, suggesting that LFA-1-mediated T cell costimulation may be involved in T cell activation at least partially through FAK.
Assuntos
Antígenos CD18/metabolismo , Complexo CD3/metabolismo , Moléculas de Adesão Celular/metabolismo , Antígeno-1 Associado à Função Linfocitária/metabolismo , Proteínas Tirosina Quinases/metabolismo , Receptores de Antígenos de Linfócitos T/metabolismo , Linfócitos T/metabolismo , Quinase 1 de Adesão Focal , Proteína-Tirosina Quinases de Adesão Focal , Humanos , Ativação Linfocitária , Fosforilação , Fito-Hemaglutininas/farmacologia , Receptor Cross-Talk , Transdução de SinaisRESUMO
Although beta1 integrin-dependent T cell migration is required for immune function, little is known of the signaling pathways regulating this migration. We now show that the cytoplasmic tyrosine kinase, focal adhesion kinase (FAK) plays an essential role in the beta1 integrin-stimulated migration of T cells through regulation of the unique Crk-associated substrate (Cas) family docking protein, human enhancer of filamentation 1 (HEF1) and effects on "outside-in" beta1 integrin signaling. Overexpression of wild-type FAK promoted beta1 integrin-dependent Jurkat T cell migration, whereas FAK mutated in either its autophosphorylation site or proline rich region 1 (PR1)/HEF1 SH3 domain-binding site had a dominant negative effect on migration. In contrast, neither wild-type nor mutant FAK affected Jurkat cell adhesion to fibronectin, a beta1 integrin ligand. The migration of FAK-overexpressing cells directly correlated with the beta1 integrin-inducible tyrosine phosphorylation of endogenous plus wild-type exogenous FAK, and not with phosphorylation of the FAK-related kinase, Pyk2. FAK was also found to regulate both HEF1-promoted migration, and HEF1 tyrosine phosphorylation in beta1 integrin-stimulated cells, in a manner dependent upon the FAK autophosphorylation and PR1 sites, and HEF1 SH3 domain. Together, our results indicate that beta1 integrin-stimulated T cell migration requires a linear beta1 integrin-FAK-HEF1 effector pathway.